---
title: Professor Lim Soon Thye
permalink: /leaders/prof-lim-soon-thye/
description: ""
third_nav_title: Executive Committee
variant: markdown
---
<img style="width:150px" src="/images/Leaders/prof%20lim%20soon%20thye.png">

##### Affiliations
* * *
**Singapore Translational Cancer Consortium**  
* Co-Director

**Singapore Health Services**  
* Deputy Group Chief Executive Officer (Research &amp; Education)
* Chief Executive Office, National Cancer Centre Singapore
* Senior Consultant, National Cancer Centre Singapore
* Associate Dean, Clinical Education, Duke-NUS Medical School
* Vice Chair, ONCO Academic Clinical Program, SingHealth Duke-NUS
* Professor, Duke-NUS Medical School


##### Profile
* * *
Professor Lim Soon Thye has been appointed as the Co-Director of the Singapore Translational Cancer Consortium since 2019. He graduated from the National University of Singapore and subsequently&nbsp;obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California. Currently, he is a senior consultant and deputy medical director (clinical) at NCCS. He also heads&nbsp;Singhealth-DukeNUS&nbsp;Blood Cancer Centre and a regular rank professor at Duke-NUS medical school.&nbsp;

His other leadership roles and positions include serving as Chairman of National Medical Residency Advisory Committee. He served as the President of Singapore Society of Oncology from 2006 to 2010;  Chairman of Chapter of Medical Oncologist and Academy of Medicine Singapore from 2011 to 2015; Council Member at the Singapore Cancer Society (SCS) where he also chairs the SCS Medical Professional and Audit Committee, as well as Cancer Treatment Fund Committee; Head of SingHealth Duke-NUS Blood Cancer Centre from 2017 to 2018; and Chairman of SingHealth Central Institutional Review Board from 2012 to 2018.

Dr Limâ€™s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centres across Asia. Dr Lim was also the principal lead investigator of a translational and clinical Research (TCR) flagship programme, Large Collaborative Grant (LCG) funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics from 2014 to 2019; Singapore lYMPHhoma TranslatiONal studY from 2019-2024). He is also conferred the title of Tanoto Professorship in Medical Oncology. Dr Lim is also part of an international team that won the AACR (American Association of Cancer Research) Team science award. The AACR Team award is a prestigious award that recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that advances our fundamental knowledge of cancer.